WO1999026660A3 - Produit a activite proliferative utile pour traiter des cellules proliferatives - Google Patents
Produit a activite proliferative utile pour traiter des cellules proliferatives Download PDFInfo
- Publication number
- WO1999026660A3 WO1999026660A3 PCT/GB1998/003509 GB9803509W WO9926660A3 WO 1999026660 A3 WO1999026660 A3 WO 1999026660A3 GB 9803509 W GB9803509 W GB 9803509W WO 9926660 A3 WO9926660 A3 WO 9926660A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- proliferation
- active
- proliferating cells
- drugs
- conjugates
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 108090000695 Cytokines Proteins 0.000 title abstract 2
- 102000004127 Cytokines Human genes 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000035755 proliferation Effects 0.000 abstract 4
- 239000013543 active substance Substances 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98955771A EP1032427A2 (fr) | 1997-11-26 | 1998-11-25 | Produit a activite proliferative utile pour traiter des cellules proliferatives |
NZ504625A NZ504625A (en) | 1997-11-26 | 1998-11-25 | Cytokines or growth factors linked to agents which control cell proliferation and pharmaceutical use |
AU12499/99A AU1249999A (en) | 1997-11-26 | 1998-11-25 | Proliferatively active product for treating proliferating cells |
JP2000521861A JP2001523731A (ja) | 1997-11-26 | 1998-11-25 | 増殖している細胞を治療するための増殖活性生成物 |
CA002311733A CA2311733A1 (fr) | 1997-11-26 | 1998-11-25 | Produit a activite proliferative utile pour traiter des cellules proliferatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9724838.9A GB9724838D0 (en) | 1997-11-26 | 1997-11-26 | Compositions |
GB9724838.9 | 1997-11-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999026660A2 WO1999026660A2 (fr) | 1999-06-03 |
WO1999026660A3 true WO1999026660A3 (fr) | 1999-10-14 |
Family
ID=10822573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/003509 WO1999026660A2 (fr) | 1997-11-26 | 1998-11-25 | Produit a activite proliferative utile pour traiter des cellules proliferatives |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1032427A2 (fr) |
JP (1) | JP2001523731A (fr) |
AU (1) | AU1249999A (fr) |
CA (1) | CA2311733A1 (fr) |
GB (1) | GB9724838D0 (fr) |
NZ (1) | NZ504625A (fr) |
WO (1) | WO1999026660A2 (fr) |
ZA (1) | ZA9810759B (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000074724A2 (fr) * | 1999-06-03 | 2000-12-14 | Bioinnovation Limited | Produits de therapie genique |
US7517887B2 (en) * | 2003-04-09 | 2009-04-14 | General Atomics | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof |
US7868011B2 (en) | 2003-04-09 | 2011-01-11 | General Atomics | Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus |
US7196093B2 (en) | 2003-04-09 | 2007-03-27 | General Atomics | Reversible inhibitors of SAH hydrolase and uses thereof |
MX347324B (es) | 2011-03-11 | 2017-04-19 | Assist Publique-Hôpitaux De Paris | Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad. |
ES2811624T3 (es) | 2011-03-11 | 2021-03-12 | Hopitaux Paris Assist Publique | Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0318948A2 (fr) * | 1987-12-02 | 1989-06-07 | Neorx Corporation | Immunoconjugués clivables pour la délivrance et libération d'agents sous forme naturelle |
EP0398305A2 (fr) * | 1989-05-17 | 1990-11-22 | Bristol-Myers Squibb Company | Conjugés d'anthracycline comportant un nouvel agent de liaison et méthodes pour leur production |
EP0510949A2 (fr) * | 1991-04-23 | 1992-10-28 | Sangstat Medical Corporation | Conjugués cytomodulateurs constants de pair liants spécifiques |
WO1993006847A1 (fr) * | 1991-10-07 | 1993-04-15 | Genentech, Inc. | Utilisation d'interferon-gamma dans le traitement d'infections chez les receveurs de greffe |
EP0624377A2 (fr) * | 1993-05-14 | 1994-11-17 | Bristol-Myers Squibb Company | Conjugués antitumoraux divables pour enzyme lysosomiales |
WO1995027732A2 (fr) * | 1994-04-08 | 1995-10-19 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Ligands et molecules chimeriques a permutation circulaire |
-
1997
- 1997-11-26 GB GBGB9724838.9A patent/GB9724838D0/en not_active Ceased
-
1998
- 1998-11-25 ZA ZA9810759A patent/ZA9810759B/xx unknown
- 1998-11-25 JP JP2000521861A patent/JP2001523731A/ja active Pending
- 1998-11-25 NZ NZ504625A patent/NZ504625A/xx unknown
- 1998-11-25 EP EP98955771A patent/EP1032427A2/fr not_active Withdrawn
- 1998-11-25 CA CA002311733A patent/CA2311733A1/fr not_active Abandoned
- 1998-11-25 WO PCT/GB1998/003509 patent/WO1999026660A2/fr not_active Application Discontinuation
- 1998-11-25 AU AU12499/99A patent/AU1249999A/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0318948A2 (fr) * | 1987-12-02 | 1989-06-07 | Neorx Corporation | Immunoconjugués clivables pour la délivrance et libération d'agents sous forme naturelle |
EP0398305A2 (fr) * | 1989-05-17 | 1990-11-22 | Bristol-Myers Squibb Company | Conjugés d'anthracycline comportant un nouvel agent de liaison et méthodes pour leur production |
EP0510949A2 (fr) * | 1991-04-23 | 1992-10-28 | Sangstat Medical Corporation | Conjugués cytomodulateurs constants de pair liants spécifiques |
WO1993006847A1 (fr) * | 1991-10-07 | 1993-04-15 | Genentech, Inc. | Utilisation d'interferon-gamma dans le traitement d'infections chez les receveurs de greffe |
EP0624377A2 (fr) * | 1993-05-14 | 1994-11-17 | Bristol-Myers Squibb Company | Conjugués antitumoraux divables pour enzyme lysosomiales |
WO1995027732A2 (fr) * | 1994-04-08 | 1995-10-19 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Ligands et molecules chimeriques a permutation circulaire |
Non-Patent Citations (6)
Title |
---|
BUKOWSKI R. M.: "Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin-2", CANCER, vol. 80, no. 7, 1 October 1997 (1997-10-01), pages 1198 - 1220, XP002097613 * |
KONIGSBERG PJ ET AL: "The development of IL-2 conjugated liposomes for therapeutic purposes.", BIOCHIM BIOPHYS ACTA, MAR 13 1998, 1370 (2) P243-51, NETHERLANDS, XP002110538 * |
MATOS DA SILVA A. C. ET AL: "Outpatient therapy with aldesleukin after autologous bone marrow transplantation", AM J. HEALTH-SYST PHARM, vol. 53, 15 July 1996 (1996-07-15), pages 1722 - 1727, XP002097614 * |
Proleukin (aldesleukin) CHIRON. January 1998 Prescribing information (United States) * |
SUNDIN D. J. ET AL: "Aldesleukin therapy in HIV infected patients", AM J. HEALTH-SYST PHARM, vol. 55, 15 July 1998 (1998-07-15), pages 1520 - 1523, XP002097615 * |
SUTHERLAND F. ET AL: "Effects of cyclosporin on C57BL/6 splenocytes before and after culture with high-dose recombinant interleukin-2: implications for immunosuppression with cyclosporin", CANCER IMMUNOL IMMUNOTHER, vol. 31, 1990, pages 312 - 320, XP002097616 * |
Also Published As
Publication number | Publication date |
---|---|
NZ504625A (en) | 2002-12-20 |
CA2311733A1 (fr) | 1999-06-03 |
GB9724838D0 (en) | 1998-01-21 |
JP2001523731A (ja) | 2001-11-27 |
EP1032427A2 (fr) | 2000-09-06 |
ZA9810759B (en) | 2000-05-25 |
WO1999026660A2 (fr) | 1999-06-03 |
AU1249999A (en) | 1999-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ye et al. | Cellular and molecular mechanisms of IFN‐γ production induced by IL‐2 and IL‐12 in a human NK cell line | |
WO1997020056A3 (fr) | Expression de genes dans des vegetaux renforcee par des activateurs | |
Salkowski et al. | Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages | |
ZA96503B (en) | Stable-lipid-comprising drug delivery complexes and methods for their production | |
HUP9801216A2 (hu) | DNS-molekulák, előállításuk és génterápiában való alkalmazásuk | |
AU7585498A (en) | Inhibition of p38 kinase activity by aryl ureas | |
NZ597270A (en) | Use of a pyrimidine nucleotide precursor for reducing side effects of a cytotoxic cancer chemotherapy agent | |
AU5121399A (en) | Rna targeted 2'-modified oligonucleotides that are conformationally preorganized | |
ATE309345T1 (de) | Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase | |
EP2058327A3 (fr) | Gènes codant des récepteurs odorants d'insectes et utilisations associées | |
IL121421A0 (en) | Oligonucleoside sequences of from about 6 to about 200 bases having a three atom internucleoside linkage and pharmaceutical compositions for inhibiting gene expression containing said oligonucleosides | |
CA2088258A1 (fr) | Oligonucleotides modifies par la pyrimidine resistants a la nuclease, detectant et modulant l'expression genique | |
CA2315647A1 (fr) | Inhibition de l'activite de p38 kinase au moyen d'urees heterocycliques aryle et heteroaryle substituees | |
WO1999026660A3 (fr) | Produit a activite proliferative utile pour traiter des cellules proliferatives | |
AU2647495A (en) | Novel potent inducers of terminal differentiation and methods of use thereof | |
AU2748701A (en) | Rapamycin analogs | |
AU8088694A (en) | 2'-amido and 2'-peptido modified oligonucleotides | |
IL128769A0 (en) | Expression of an exogenous gene by us of a non-mammalian dna virus | |
EP2028274A3 (fr) | Un oligonucléotide antisens dirigé contre le gène de TGF-beta2 | |
Shockett et al. | Inhibitors of poly (ADP-ribose) polymerase increase antibody class switching. | |
AU3295700A (en) | Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same | |
WO2001026629A3 (fr) | Lipide cationique-neutre destine a l'apport d'acides nucleiques et de medicaments | |
DK0426521T3 (da) | Anvendelse af interleukin 2 til behandling af leukæmi | |
AU4848793A (en) | Oligonucleotide and nucleotide amine analogs, methods of synthesis and use | |
WO1999058656A3 (fr) | Liberation prolongee d'adn depuis des matrices structurales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12499/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 504625 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2311733 Country of ref document: CA Ref country code: CA Ref document number: 2311733 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998955771 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998955771 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998955771 Country of ref document: EP |